What is ReceptivaDx?

ReceptivaDx is a test that measures BCL6, a marker highly associated with endometriosis. Studies have shown that women with elevated BCL6 results are 5 times less likely to succeed in IVF or subsequent transfer attempts compared to a patient that test negative for BCL6. A negative BCL6 result provides reassurance to patients that endometriosis is not of concern. While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDx™ can accurately detect inflammatory conditions on the uterine lining likely to cause implantation issues.



Who is a candidate for testing?

Candidates for ReceptivaDx testing include:

  • All women with unexplained infertility
  • Women who have failed one or more IVF cycles
  • Women who have experienced recurrent pregnancy loss
  • Women who cannot afford IVF or that have limited fertility coverage



How does endometriosis impact IVF?

Undetected endometriosis interferes with the ability of a fertilized egg to implant. Endometriosis can block successful implantation regardless of how a woman gets pregnant, through normal sexual intercourse or IVF. While many patients hear about endometriosis in women who have experienced pelvic pain, painful intercourse or heavy bleeding during menses, milder forms without symptoms can be present without experiencing any physical symptoms. These milder forms of endometriosis are often undetectable and cannot always be visualized through ultrasound or laparoscopy. This is the power and benefit to patients by having the ReceptivaDx test performed.


Dr. Aimee
San Ramon, CA
Draimee.org

“I was one of the early adopters of the ReceptivaDx test. Our experience has exceeded my expectations. We can now identify and treat women with early endometriosis who might have gone undetected before. For our patients, this has led to improved success rates, reduced costs and the avoidance of multiple IVF cycles. “

How is the test performed?

The ReceptivaDx Test is performed on an endometrial biopsy sample, a routine procedure that can be performed during a normal office visit with your Ob-Gyn or Reproductive Specialist. The biopsy can be taken during a natural or mock cycle, but must be taken during the window of implantation.

Defining Your ReceptivaDx Biopsy Date Range:

Natural Cycle:
6-10 days after LH surge
7-10 days after ovulation occurs

Mock Cycle:
5-10 days after start of progesterone

Once collected, the sample is placed in a preservative (10% formalin vial) and is sent overnight via FedEx to our testing facility. Upon arrival, biopsies are processed and evaluated by our pathology team. A full pathology report is then prepared and submitted to your physician. Results are usually available in 3-4 business days. Samples are stable at room temperature during the entire shipping process and can be collected any day of the week. Our ReceptivaDx Collection Kit comes complete with everything necessary to properly collect and submit a sample.

What treatment options are available if I test positive?

If found to be positive for BCL6, endometriosis is likely. A treatment plan involving hormone therapy or laparoscopy to remove visible endometriosis can correct the situation. Patients undergoing 60-90 days of hormone therapy have shown excellent success in achieving pregnancy and live births by our IVF centers (publications pending).

How and where can I get the test done?

Any fertility center or Ob-Gyn office performing endometrial biopsies can collect a sample for ReceptivaDx testing. A list of fertility centers offering ReceptivaDx routinely to their patients can be found on our website. Collection kits are provided to physician offices at no-charge. We can also arrange shipments of collection kits for patients to bring into offices that don’t currently stock our kits. If you need help finding a center near you, please contact our customer service desk at 800-795-5385.



What does the test cost?

The cost of the ReceptivaDx test is $690 dollars. This includes costs associated with shipping the kit overnight via FedEx to our nearest licensed testing center. CD138, a marker that identifies endometritis and Beta3 Integrin, a test for uterine receptivity, can also be ordered for an additional $125 a marker.

ReceptivaDxTM require payment via credit card at the time of sample submission. Patients may call our offices to make payment in advance if preferred. CiceroDx provides a detailed receipt that can be used for potential reimbursement from insurance or healthcare spending accounts. Please provide an email address on the test request form to receive the detailed receipt.

International customers are responsible for the cost of shipping to our testing centers in the US.

Who is CiceroDx?

CiceroDx, Inc. is a diagnostics company dedicated to the advancement of clinical assays in women’s healthcare. CiceroDx has exclusive rights to BCL6 analysis on endometrial tissue. Our company has forged relationships with key academic research centers and is dedicated to the development of new testing modalities for endometriosis and unexplained infertility.

CiceroDx maintains two laboratory locations in the US. Both testing sites operate under CLIA guidelines established for best laboratory practices and are fully licensed. CiceroDx is the only licensed provider in the US for detection of the BCL6 marker in endometrial biopsy samples.

Please feel free to contact us at 800-795-5385 for further information. International clients can email us at info@cicerodx.com or call us at 1-714-951-9245.

Subscribe to our newsletter and stay up to date with ReceptivaDx.
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
© 2018 Receptivadx. All Rights Reserved